By Stephen Nakrosis
Shares of Idera Pharmaceuticals Inc. were trading higher in Wednesday's after-hours market, following news that the company acquired privately held Aceragen Inc.
At 5:51 p.m. ET, Idera's shares had risen 17.76% to trade at 47 cents a share. Volume at the time topped 101,000 shares. The stock finished the day's regular session with a 3.73% gain, closing at 38 cents per share.
The acquisition includes ACG-701, "a proprietary formulation of sodium fusidate being developed as a potential treatment for acute pulmonary exacerbations associated with cystic fibrosis and for melioidosis, a life-threatening infection caused by the B. pseudomallei pathogen," Idera said.
Additionally, the acquisition includes ACG-801, an "investigational biologic enzyme replacement therapy being developed for the treatment of Farber disease," the company said.
Idera also named John Taylor, the former chief executive of Aceragen, to succeed CEO Vincent Milano, who was named chair of the board.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 28, 2022 18:15 ET (22:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。